

Amendments to the Specification

Please replace the paragraph at page 50, lines 23-29, of the specification with the following amended paragraph:

Non-limiting examples of compounds that cause an alteration in late endosomal/lysosomal trafficking of cholesterol include U18666A (~~formula VII~~) (formula VIII) and its derivatives (~~e.g., formulae II-VI~~) (e.g., formulae II-VII), either alone or in combination. Useful examples of U18666A derivatives include CP-598755-01 (formula III), CP-602367 (formula IV), CP-352369 (formula II), UK-204039 (formula V), UK-204041 (formula VI), and UK-204042 (formula VII). Generic formula I presented herein is derived from U18666A and its derivatives presented herein (also see Figure 16).

Please replace the paragraph at page 81, lines 26-32, of the specification with the following amended paragraph:

The results are presented in Figure 19 (small granule fractionation) and ~~Figure 8~~ Figure 20 (large granule fractionation). These data indicate that the localization of tyrosinase is markedly affected by exposure to U18666A. For example, in Figure 19 a shift in the distribution of tyrosinase is evident in comparing fraction 5 of the control and U18666A samples. The change in the distribution of tyrosinase is even more evident in the large granule fractionation study (*see* Figure 20, fractions 6-8, for the large granule fraction control (LGF-C) and large granule fraction U18666A (LGF-U18)).